Overview

Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study

Status:
Not yet recruiting

Trial end date:
2025-09-24

Target enrollment:

Participant gender:

Summary

This is a single-arm, open, multicenter phase II clinical study to evaluate the efficacy and safety of HL-085 capsules combined with Vemurafenib in the treatment of BRAF V600E mutated patients with unresectable locally advanced or metastatic NSCLC. Meanwhile, to explore the relationship between pop-PK characteristics, efficacy and safety in the treatment of HL-085 combined with Vemurafenib

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Kechow Pharma, Inc.

Treatments:

Vemurafenib